Symbol="IMTX"
AssetType="Common Stock"
Name="Immatics NV"
Description="Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany."
CIK="1809196"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="PAUL EHRLICH-STRASSE 15, TUBINGEN, DE"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="968874000"
EBITDA="-61604000"
PERatio="None"
PEGRatio="None"
BookValue="2.61"
DividendPerShare="0"
DividendYield="0"
EPS="-1.19"
RevenuePerShareTTM="1.128"
ProfitMargin="-0.852"
OperatingMarginTTM="-0.815"
ReturnOnAssetsTTM="-0.123"
ReturnOnEquityTTM="-0.43"
RevenueTTM="79720000"
GrossProfitTTM="172831000"
DilutedEPSTTM="-1.19"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.905"
AnalystTargetPrice="18.18"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.703"
PriceToBookRatio="6.18"
EVToRevenue="2.833"
EVToEBITDA="9.92"
Beta="0.501"
num_52WeekHigh="13.6"
num_52WeekLow="5.9"
num_50DayMovingAverage="11.57"
num_200DayMovingAverage="9.54"
SharesOutstanding="76672000"
DividendDate="None"
ExDividendDate="None"
symbol="IMTX"
open="11.77"
high="12.34"
low="11.77"
price="12.02"
volume="127516.00"
latest_trading_day="2023-08-10"
previous_close="11.99"
change="0.03"
change_percent="0.2502%"
aroon_positive_momentum_days="70"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="70"
Volume_recent_avg="454366"
Change_recent_avg="0.01"
Delta_recent_avg="0.56"
Variance_recent_avg="0.28"
Change_ratio_recent_avg="-0.09"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="70"
Aroon_momentum_negative="30"
image_negative_thumbnail_id_1="151"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0025.jpeg"
image_negative_thumbnail_id_2="1095"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0128.jpeg"
image_neutral_thumbnail_id_1="574"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_neutral_thumbnail_id_2="563"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_positive_thumbnail_id_1="984"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0146.jpeg"
image_positive_thumbnail_id_2="626"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0082.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1173"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
